Wohua Pharmaceutical lost nearly 100 million yuan, what are the reasons, and there can be an investi

Net profit of 10,000 yuan, 10,000 yuan, 10,000 yuan, from the first quarter to the third quarter of this year, Wohua Pharmaceutical's performance is becoming more and more miserable. In the third quarterly report, Wohua Pharmaceutical expects a loss of 95 million to 100 million this year. Last year's newly acquired Tongluo Huaphlegm Capsule did not become a good medicine to save the performance of Wohua Pharmaceutical, as the company hoped; The long-awaited "National Essential Medicines List (Extended Edition)" also does not know when it will appear.

Since its launch in 2007, Wohua has probably never felt so helpless. Wohua Pharmaceutical is mainly engaged in the research and development, production and sales of cardiovascular and cerebrovascular Chinese patent medicines, and its main products include Xinkeshu tablets, cerebral blood thinning oral liquid, amber stone granules, and kite cold granules. In fact, from the end of 2008 to the first half of 2009, Wohua Pharmaceutical had a good performance, reaching a peak of 51 yuan shares in July 2009, and on the 10th of the same month, every 10 shares increased by 10 shares.

But as of yesterday**, Wohua Pharmaceutical has fallen to the yuan stock. The bane of Wohua Pharmaceutical's huge losses has been the bane of the National Essential Medicines List (grassroots) on August 18 last year.

You can take a questionnaire online, for example, a Q&A website.

Summary. Wohua Pharmaceutical's low earnings per share may be due to the following reasons:1

The company's revenue growth was affected, resulting in insufficient profits, which in turn affected earnings per share; 2.The company issued a large number of **, which led to an increase in share capital, and earnings per share naturally declined; 3.The company has a lot of expenses that are not included in costs in advance, as well as a large number of profit distributions, dividends, capital expenditures, etc., which can also affect earnings per share; 4.

Affected by macro factors such as industry competition, the company's sales ** declined, gross profit margin decreased, and profits declined, which will also affect earnings per share.

Can you add, I don't quite understand it.

Wohua Pharmaceutical's low earnings per share may be due to the following reasons:1The company's revenue growth was affected, resulting in insufficient profits, which in turn affected earnings per share; 2.

The company issued a large number of **, which led to an increase in share capital, and earnings per share naturally declined; 3.The company has a lot of expenses that are not included in the cost in advance, as well as a large number of profit distributions, dividends, capital expenditures, etc., which will also affect the income per share; 4.Affected by macro factors such as industry competition, the company's sales will decline, gross profit margin will decrease, and profits will decline, which will also affect earnings per share.

Scale growth metrics.

In the past three years, the average sales growth rate of Wohua Pharmaceutical is 697 1710 among all listed companies, and 30 90 in the pharmaceutical industry where it is located.

EPS growth.

In the past, the EPS growth rate of Wohua Pharmaceutical was ranked 870 1710 among all listed companies, and 53 90 in the pharmaceutical industry where it is located, and the company's growth is reasonable.

Profitability metrics.

The average profitability growth rate of Wohua Pharma in the past three years is 797 1710 among all listed companies and 51 90 in the pharmaceutical industry. Profitability is reasonable.

EPS stability.

In the past, Wohua Pharma was ranked in EPS stability among all listed companies (275 1710), and its pharmaceutical industry was ranked 11 90. The company's operation is stable and good.

No. Name of Shareholder Number of Shares Shareholding Proportion Nature of Share Capital 1 Beijing CSI Wanrong Investment Group **** 10,000 Restricted Shares 2 Wang Jiayu 10,000 A Shares Circulated, Restricted Shares 3 Zhao Jun 10,000 A Shares Tradable, Tradable Restricted Shares 4 Zhang Ge Wan Tradable A Shares, Tradable Restricted Shares 5 Zhang Fazhong Wan Tradable A Shares, Tradable Restricted Shares 6 Tian Kaiji Wan Tradable A Shares, Tradable Restricted Shares 7 Huang Xianlan Wan Tradable A Shares, Tradable Restricted Shares 8 Beijing Mingkun Investment**** 10,000 Tradable Restricted Shares 9 Haitong ** Shares**** 10,000 Tradable restricted shares 10 Dalian Huaxing Garment **** million tradable restricted shares.

No. Name of Shareholder Number of Shares Shareholding Proportion Nature of Share Capital 1 Beijing CSI Wanrong Investment Group **** 10,000 Restricted Shares 2 Wang Jiayu 10,000 A Shares Circulated, Restricted Shares 3 Zhao Jun 10,000 A Shares Tradable, Tradable Restricted Shares 4 Zhang Ge Wan Tradable A Shares, Tradable Restricted Shares 5 Zhang Fazhong Wan Tradable A Shares, Tradable Restricted Shares 6 Tian Kaiji Wan Tradable A Shares, Tradable Restricted Shares 7 Huang Xianlan Wan Tradable A Shares, Tradable Restricted Shares 8 Beijing Mingkun Investment**** 10,000 Tradable Restricted Shares 9 Haitong ** Shares**** 10,000 Tradable restricted shares 10 Dalian Huaxing Garment **** million tradable restricted shares.

2 Wang Jiayu Wan A shares are tradable, and restricted shares are tradable.

3 Zhao Jun Wan A shares are tradable, and restricted shares are tradable.

4 Zhang Ge Wan A shares are tradable, and restricted shares are tradable.

5 Zhang Fazhong 10,000 A shares are tradable, and restricted shares are tradable.

6 Tian Kaiji Wan A shares are tradable, and restricted shares are tradable.

7 Huang Xianlan 10,000 A shares are tradable, and restricted shares are tradable.

8 Beijing Mingkun Investment **** million circulating restricted shares.

9 Haitong ** shares **** million circulating restricted shares.

10 Dalian Huaxing Garment **** million circulating restricted shares.

Comprehensive investment advice: The comprehensive score of Wohua Pharmaceutical (002107) shows that the investment value of the stock is average ( The valuation range of the stock is between yuan and the stock price is currently in the undervalued area, so you can hold it with confidence.

12-Step Value Appraisal Investment Advice: Based on the 12-step evaluation of the stock, the stock is worth investing in better ( It is recommended that you take an attitude of participation in the stock.

Industry Rating Investment Advice: Wohua Pharmaceutical (002107) belongs to the pharmaceutical industry, and the current investment value of the industry is average ( The overall ranking of this industry is 12th.

Growth Quality Rating Investment Suggestions: Wohua Pharmaceutical (002107) has poor growth ability ( The development potential in the next three years is very small ( ) The stock ranks 701st in terms of overall growth ability and 44th in the growth ability of its industry.

Rating & Earnings**: Wohua Pharma (002107)** 2009 EPS, 2010 EPS, 2011 EPS of RMB, current target price of RMB, investment rating of Hold.

1.The company's flagship product, Xinkeshu tablets, is a high-quality and high-price variety, and the ex-factory price and the highest retail price in 2007 were qualified to raise prices, and the new ** began to be implemented in 2008, which had a slag impact on the company's performance.

2.The company has been recognized as a high-tech enterprise with a validity period of three years. According to the relevant regulations, the company has been recognized as a high-tech enterprise within three years (2008 to 2010), and enjoys the preferential tax policy of leviing enterprise income tax at a rate of 15%.

3.The company's main financial indicators in the first three quarters of 2009: earnings per share), net assets per share), return on net assets, operating income yuan), year-on-year increase or decrease; net profit attributable to shareholders of listed companies), year-on-year increase or decrease.

4.The company's 2008 capital reserve to increase share capital plan is: 10 shares for every 10 shares.

Record date: July 9, 2009; Ex-date: July 10, 2009 New listing date of unrestricted tradable shares:

10 July 2009.

5.The number of shares released by the company is 24 million shares, and the actual number of shares that can be listed and circulated is 24 million shares, and the listing and circulation date is August 27, 2009.

6.The company and Beijing Tiantaiyuan Pharmaceutical Technology Development **** signed the "new drug "Tongluo Hua Phlegm Capsule" production technology and patent cooperation agreement, the company intends to exclusively transfer the latter's Tongluo Hua Phlegm Capsule production and sales rights for 10 years.

Shandong Wohua Pharmaceutical Technology Co., Ltd. is a Chinese patent medicine manufacturer with a history of 100 years, and its history can be traced back to Wanhetang Pharmaceutical Village during the Qianlong period of the Qing Dynasty. At that time, Wanhetang Pharmacy, the front store and the back factory, enjoyed a good reputation in the central Luzhong area. After the liberation, the public-private partnership established Shandong Weifang Traditional Chinese Medicine Factory in January 1959 on the basis of the Chinese Medicine Processing Department of Wanhetang Pharmaceutical Village and the decoction piece processing group of Shandong Changwei Central Medicinal Materials Company.

In February 2002, it was restructured into Weifang Wohua Pharmaceutical Science and Technology. In March 2003, with the approval of the people of Shandong Province, it was changed to Shandong Wohua Pharmaceutical Technology Co., Ltd., which is one of the key manufacturers of Chinese patent medicine in Shandong Province. On January 24, 2007, the company was officially listed on the Shenzhen Stock Exchange, becoming the first listed pharmaceutical company in Weifang City, and on August 8, 2008, Wohua Pharmaceutical was successfully privately issued.